Top

BMC Cancer

Published in:

01-12-2021 | Hepatocellular Carcinoma | Research article

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

Authors: Honglei Feng, Bole Li, Ze Li, Qian Wei, Li Ren

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system and has high morbidity and mortality rates. It is essential to search new biomarkers to improve the accuracy of early HCC diagnosis. Therefore, we evaluated the diagnostic value of prothrombin induced by vitamin K deficiency or antagonist- II (PIVKA-II) as a potential biomarker that complements α-fetoprotein (AFP) in HCC by detecting the serum PIVKA-II levels.

Methods

Serum PIVKA-II levels were compared in 168 HCC patients, 150 benign liver disease patients and 153 healthy controls to investigate the PIVKA-II potential to be a HCC biomarker. Receiver operating characteristic curve (ROC) analysis was used to evaluate the value of PIVKA-II in the diagnosis of HCC and its complementary role of AFP. The correlation between serum PIVKA-II levels and clinicopathological characteristics was analyzed to study the value of PIVKA-II in assessing HCC progression and prognosis. Finally, the ability of PIVKA-II in assessing the surgical treatment effects of HCC was studied by comparing the pre- and post-operative serum PIVKA-II levels in 89 HCC patients.

Results

Serum PIVKA-II levels in HCC patients were significantly higher than that in patients with benign liver disease and healthy controls. The PIVKA-II performance in the diagnosing HCC as an individual biomarker was remarkable. The combined detection of PIVKA-II and AFP improved the diagnostic efficiency of HCC. PIVKA-II retained significant diagnosis capabilities for AFP-negative HCC patients. Significant correlations were found between PIVKA-II expression levels and some clinicopathological characteristics, including tumor size, tumor stage, tumor metastasis, differentiation degree and complications. PIVKA-II expression obviously decreased after surgical resection.

Conclusions

PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC. The PIVKA-II levels in HCC patients were widely associated with clinicopathological characteristics representing tumor cell dissemination and/or poor prognosis. PIVKA-II can be used to evaluate the curative effects of HCC resection.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70. https://doi.org/10.1007/s12072-017-9799-9.CrossRefPubMed

Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–63. https://doi.org/10.21037/hbsn-20-480.CrossRefPubMedPubMedCentral

Sarbarzeh PA, Karimi S, Jalilian M, et al. Depression, Anxiety, Stress and Social Isolation in Hepatitis Patients. SciMedicine J. 2020;2(4):225–33.CrossRef

Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, et al. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scand J Gastroenterol. 2018;53(6):734–40. https://doi.org/10.1080/00365521.2018.1459824.CrossRefPubMed

Sartorius K, Sartorius B, Winkler C, et al. The biological and diagnostic role of miRNA's in hepatocellular carcinoma. Front Biosci (Landmark Ed). 2018;23:1701–20.CrossRef

Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis. Cancer Biol Med. 2018;15(2):124–36. https://doi.org/10.20892/j.issn.2095-3941.2018.0018.CrossRefPubMedPubMedCentral

Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol. 2013;19(3):339–46. https://doi.org/10.3748/wjg.v19.i3.339.CrossRefPubMedPubMedCentral

Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16(7):453–63. https://doi.org/10.1111/j.1365-2893.2009.01117.x.CrossRefPubMed

Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–12. https://doi.org/10.1016/j.jhep.2005.05.028.CrossRefPubMed

10.

Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139(8):1417–24. https://doi.org/10.1007/s00432-013-1458-5.CrossRefPubMed

11.

Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, et al. Keratin 19, a Cancer stem cell marker in human hepatocellular carcinoma. Clin Cancer Res. 2015;21(13):3081–91. https://doi.org/10.1158/1078-0432.CCR-14-1936.CrossRefPubMed

12.

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31. https://doi.org/10.1056/NEJM198405313102204.CrossRefPubMed

13.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14(2):470–7. https://doi.org/10.1158/1078-0432.CCR-07-0586.CrossRefPubMed

14.

Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009;115(3):571–80. https://doi.org/10.1002/cncr.24031.CrossRefPubMed

15.

Yavari K. Anti-Angiogenesis Therapy of Cancer Cells using ¹⁵³Sm-Bevasesomab. Emerg Sci J. 2018;2(3):130–9.CrossRef

16.

Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol. 2019;54(10):1283–90. https://doi.org/10.1080/00365521.2019.1673478.CrossRefPubMed

17.

Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998;82(9):1643–8. https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1643::AID-CNCR8>3.0.CO;2-B.CrossRefPubMed

18.

Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol. 1999;94(3):650–4. https://doi.org/10.1111/j.1572-0241.1999.00930.x.CrossRefPubMed

19.

Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol. 2005;11(39):6115–9. https://doi.org/10.3748/wjg.v11.i39.6115.CrossRefPubMedPubMedCentral

20.

Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3928–35. https://doi.org/10.3748/wjg.v21.i13.3928.CrossRefPubMedPubMedCentral

21.

Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39(4):434–9. https://doi.org/10.1053/j.seminoncol.2012.05.009.CrossRefPubMed

22.

Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006;101(9):2038–43. https://doi.org/10.1111/j.1572-0241.2006.00681.x.CrossRefPubMed

23.

Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer. 2000;88(3):544–9. https://doi.org/10.1002/(SICI)1097-0142(20000201)88:3<544::AID-CNCR8>3.0.CO;2-F.CrossRefPubMed

24.

Loglio A, Iavarone M, Facchetti F, di Paolo D, Perbellini R, Lunghi G, et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int. 2020;40(8):1987–96. https://doi.org/10.1111/liv.14475.CrossRefPubMed

25.

Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol. 2001;16(11):1290–6. https://doi.org/10.1046/j.1440-1746.2001.02610.x.CrossRefPubMed

26.

Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87(4):531–7. https://doi.org/10.1097/TP.0b013e3181943bee.CrossRefPubMed

27.

Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91(3):561–9. https://doi.org/10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N.CrossRefPubMed

28.

Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17(1):608. https://doi.org/10.1186/s12885-017-3609-6.CrossRefPubMedPubMedCentral

29.

Zhang D, Liu Z, Yin X, Qi X, Lu B, Liu Y, et al. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: a systematic review and meta-analysis. Int J Biol Markers. 2018;33(3):266–74. https://doi.org/10.1177/1724600818760234.CrossRefPubMed

30.

Shimada S, Kamiyama T, Orimo T, Nagatsu A, Asahi Y, Sakamoto Y, et al. Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy. World J Surg Oncol. 2020;18(1):122. https://doi.org/10.1186/s12957-020-01899-4.CrossRefPubMedPubMedCentral

Title: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
Authors: Honglei Feng
Bole Li
Ze Li
Qian Wei
Li Ren
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08138-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Central neck lymph node metastasis in oral squamous cell carcinoma at the floor of mouth

Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin

Blood pressure and risk of cancer: a Mendelian randomization study

DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database

Correction to: KDM6B promotes ESCC cell proliferation and metastasis by facilitating C/EBPβ transcription

Keynote webinar | Spotlight on antibody–drug conjugates in cancer